Skip to main content
Reimbursement strategy

Market Access Strategy for Medical Devices in Europe

Strategic recommendations on the topic of market access pathways for medical devices and IVD tests

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

EU HTA Publication Digest: The Early Experiences of Health Technology Assessment Bodies in the Implementation of the European Union Health Technology Assessment Regulation for High-Risk Medical Devices: A Qualitative Study

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. 

In a recent publication, Alshaikh et al. explored how national HTA bodies across 11 EU Member States are preparing for the implementation of the EU Health Technology Assessment Regulation (HTAR) and the introduction of Joint Clinical Assessments (JCAs) for high-risk medical devices and IVDs. The study identified broad recognition of JCAs as a mechanism to enhance evidence quality and enable work sharing, particularly for smaller HTA systems with limited resources. However, many agencies remain in a preparatory or observational phase. Regulatory uncertainty, timeline misalignment, and concerns about manufacturer readiness emerged as key barriers to effective implementation.

Access the full-text article here.